[Docetaxel in the treatment of advanced breast cancer ].
OBJECTIVE
To evaluate the efficacy, toxicity and safety of an new domestic docetaxel in the treatment of pretreated advanced breast cancer.


METHODS
Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial. They received docetaxel as the second-line chemotherapy. Docetaxel was administered alone at a dose of 70 mg/m2 every 3 weeks. The use of granulocyte colony-stimulating factor to prevent granulocytopenia was not permitted. The response rate and toxicity were evaluated by World Health Organization toxicity scale and performance status by Karnofsky scale.


RESULTS
Of the 41 evaluable patients, 4 achieved complete response and 14 partial remission, with a response rate and clinical benefit rate of 43.9% and 85.4%, respectively. Grade 3 or grade 4 neutropenia developed in 42.9%, alopecia in 7.1% and vomiting in 4.8% of these patients. Fluid retention was not observed in this series.


CONCLUSIONS
Three-week administration of docetaxel alone at a dose of 70 mg/m2 is effective and tolerable. It provides an alternative for the pretreated advanced breast cancer patients.
Wang
Zi-Ping
ZP
Department of Medical Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. pingziwang@yahoo.com
Sun
Yan
Y
Zhang
Xiang-Ru
XR
Zhang
Mao-Hong
MH
Wang
Xiu-Wen
XW
Yu
Xue-Jun
XJ
Nan
Ke-Jun
KJ
Li
En-Xiao
EX
Liu
Ji-Wei
JW
Gao
Ya-Jie
YJ
Guan
Xiao-Qian
XQ
Song
Shu-Ping
SP
Sheng
Li-Jun
LJ
Wang
Dong-Lin
DL
Wang
Zhi-Xin
ZX
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D012074:Remission Induction; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel